Palisade Bio, Inc. (NASDAQ:PALI – Free Report) – Equities researchers at HC Wainwright lowered their Q2 2026 EPS estimates for Palisade Bio in a research note issued to investors on Wednesday, May 13th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.04) per share for the quarter, down from their previous estimate of ($0.02). HC Wainwright has a “Buy” rating and a $7.00 price objective on the stock. The consensus estimate for Palisade Bio’s current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Palisade Bio’s Q3 2026 earnings at ($0.04) EPS, Q4 2026 earnings at ($0.05) EPS, FY2026 earnings at ($0.18) EPS, Q1 2027 earnings at ($0.05) EPS, Q2 2027 earnings at ($0.05) EPS, Q3 2027 earnings at ($0.05) EPS, Q4 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.21) EPS.
Other equities research analysts have also issued reports about the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Palisade Bio in a research note on Thursday, January 22nd. Wall Street Zen raised shares of Palisade Bio from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Wolfe Research assumed coverage on shares of Palisade Bio in a research note on Thursday, April 9th. They set an “outperform” rating and a $7.00 target price on the stock. Finally, Stifel Nicolaus assumed coverage on shares of Palisade Bio in a research note on Wednesday, February 25th. They set a “buy” rating and a $5.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.20.
Palisade Bio Stock Down 3.2%
PALI stock opened at $1.81 on Friday. The company’s 50-day simple moving average is $1.98 and its 200-day simple moving average is $1.93. Palisade Bio has a 52-week low of $0.53 and a 52-week high of $2.86. The firm has a market cap of $303.04 million, a P/E ratio of -1.27 and a beta of 1.52.
Palisade Bio (NASDAQ:PALI – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.01).
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the stock. Cetera Investment Advisers acquired a new position in shares of Palisade Bio during the 4th quarter worth about $25,000. Schonfeld Strategic Advisors LLC acquired a new position in shares of Palisade Bio during the 4th quarter worth about $26,000. Virtu Financial LLC acquired a new position in shares of Palisade Bio during the 4th quarter worth about $28,000. Atom Investors LP acquired a new position in shares of Palisade Bio during the 4th quarter worth about $33,000. Finally, Barclays PLC acquired a new position in shares of Palisade Bio during the 4th quarter worth about $35,000. Institutional investors and hedge funds own 11.79% of the company’s stock.
Palisade Bio Company Profile
Palisade Bio, Inc is a clinical‐stage biotechnology company focused on pioneering localized immunotherapies for the treatment of cancer and inflammatory diseases. The company leverages a proprietary prodrug platform designed to activate therapeutic agents selectively within the tumor microenvironment or sites of inflammation. Its core strategy centers on stimulating the innate immune system via toll‐like receptor 9 (TLR9) agonism to drive targeted immune responses while minimizing systemic exposure and toxicity.
The company’s lead product candidate, PDS0108, is an intratumoral TLR9 agonist prodrug currently in Phase 1/2 clinical trials for patients with advanced solid tumors.
Recommended Stories
- Five stocks we like better than Palisade Bio
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for Palisade Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palisade Bio and related companies with MarketBeat.com's FREE daily email newsletter.
